Email Sign-up
Register | Login
The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
NEWS
CONFERENCES
VIDEOS
Interviews
Investigator Perspectives
Case-Based Peer Perspectives
PUBLICATIONS
Evolving Paradigms
Targeted Therapies in Oncology
The Journal of Targeted Therapies in Cancer
ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer

Specialties >>

Acute Myeloid Leukemia
Biosimilars
Bladder Cancer
Brain Cancer
Breast Cancer
Chronic Lymphocytic Leukemia
Colorectal Cancer
Follicular Lymphoma
Gastric Cancer
Gastrointestinal Cancers
Genitourinary Cancers
Gynecologic Cancers
Head and Neck Cancers
Hematology
HER2- Breast Cancer
Immunotherapy
Lung Cancer
Lymphomas
Mantle Cell Lymphoma
Melanoma
Multiple Myeloma
Ovarian Cancer
Prostate Cancer
Renal Cell Carcinoma
Soft Tissue Sarcoma

Partners >>

Dialogues in Diagnostics
Differential Diagnosis
Case-Based Peer Perspectives
Email Sign-Up

Evolving Paradigms
Non-Small Cell Lung Cancer

Clinical Articles

Therapeutic Options Developing for Nondriver NSCLC, But Challenges Remain
Nonbiomarker NSCLC Population a Challenging Obstacle, Expert Says
Nonbiomarker, Nonsquamous NSCLC: Diagnosis, Statistics, Staging, and Testing
Current Treatment Strategies in Nonbiomarker Nonsquamous NSCLC
Emerging Treatment Strategies in Nonsquamous NSCLC
Dr. Bazhenova on the Treatment Landscape of Non-Driver NSCLC
Dr. Bazhenova on Remaining Challenges and Future Treatment Landscape of Non-Driver NSCLC
Dr. Bazhenova on Potential Impact of Immunotherapy in Non-Driver NSCLC
Dr. Bazhenova on Considering Factors to Treat Non-Driver Patients With NSCLC With Bevacizumab
Dr. Bazhenova on Current Treatment Strategies for Patients With Nonsquamous NSCLC
Dr. Bazhenova on the Prevalence of Patients With Non-Driver NSCLC
Dr. Langer Discusses Remaining Challenges With the Non-Driver NSCLC Population
Dr. Langer Discusses Ongoing Clinical Trials for Patients With Non-Driver NSCLC
Dr. Langer Discusses Current Treatment Strategies for Patients With Non-Driver Nonsquamous NSCLC
Dr. Langer Discusses the Prevalence of Patients With Non-Driver NSCLC
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.